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Summary. The  object ive of this study was the 
evaluation of the relation between the N-acetyl- 
neuraminic acid-binding endogenous lectin sarcolectin 
and the cytokine macrophage migration inhibitory factor 
(MIF) during development of rheumatoid nodules (RN) 
in seropositive rheumatoid arthritis (RA). Sarcolectin 
was purified and biotinylated. The binding patterns of 
this probe were analyzed in RN from patients with RA 
(n=23) and compared with the distribution of antibodies 
with specificity for MIF, fibrin, fibronectin. In early RN, 
all areas of the inflammatory tissue displayed presence 
of receptors for sarcolect in .  Macrophages were 
especially positive. In mature rheumatoid nodules 
binding of sarcolectin was restricted to the periphery of 
necrotic areas, to endothelial cells and perivascular 
connective tissue of marginal zones. Distribution 
patterns of MIF were similiar but not identical. The 
histological s ta ining characteristics demonstrate  
sarcolectin-binding receptors in RN that are altered upon 
disease progression. The finding suggests that specific 
interactions between this endogenous lectin and MIF 
may be involved in the course of RA. 
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Introduction 
Rheumatoid nodules  (RN) are the result  of a 
necrotising process particularly associated with 
rheumatoid factor-positive rheumatoid arthritis (RA). 
They are commonly detected in the subcutaneous tissue 
overlying bony prominences (Gordon and Hastings, 
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1998). In its fully developed form, the lesion (Fig. 1) 
demonstrates  a character is t ic  histopathological 
morphology (Fassbender,  1994). An intermediate 
cellular zone of elongated epitheloid cells, composed 
mainly of activated macrophages surrounds a central 
necrotic mass. The marginal connective tissue consists 
of an inner sector that contains inflammatory cell 
infiltrates, mostly isolated macrophages, which merge 
with the radially arranged palisading cells. Whereas this 
area is largely devoid of vasculature, the outer sector 
shows aggregations of small vessels that are surrounded 
by lymphocytes  and plasma cells.  Although the 
morphology of the RN has been subject of numerous 
investigations, the pathogenic mechanism of its 
formation has been open to debate. According to current 
evidence mechanical trauma and aggregation of 
rheumatoid factors initiate the granulomatous reaction of 
connective tissue (Ziff, 1990). It has been suggested that 
attraction and activation of macrophages is the main 
mechanism of the necrotising process (Palmer et al., 
1987). Staining with proliferation markers such as Ki67 
has provided evidence that aggregation of palisaded 
macrophages is a consequence of vascular influx and not 
from cell proliferation (Lalor et al., 1987). Enhanced 
secretion of cytotoxic enzymes and coagulation factors 
may result in deposition of cell  remnants and 
inflammatory-induced molecules such as fibrin and 
fibronectin. 
Numerous factors,  besides rheumatoid factor 
immune complexes,  have been implicated in the 
pathogenesis of RNs by inducing monocyte chemotaxis 
and inflammatory stimulation (Arend et al., 1982). 
Examples are interferon-y, interleukin 1, tumour necrosis 
factor a, transforming growth factor B and complement 
components (Chantry et al., 1989; Brennan et al., 1997; 
Langdon et al., 1997). As indicated by its name, the 
human lymphokine macrophage migration inhibitory 
factor (MIF) belongs to this group of effectors with 
impact on monocyte mobility; the pathways for 
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activation between different elicitors being different 
(Herriot et al., 1993). Since this factor is assumed to play 
a critical role in immune regulation and in the systemic 
response to tissue invasion, its expression in disease- 
affected tissue can provide relevant information 
(Calandra et al., 1994). In this respect, it is noteworthy 
that MIF has been described to be the major binding 
protein of an a-/&interferon antagonist and growth 
promotor in human placenta, named sarcolectin (Zeng et 
al., 1993). This protein has lectin-like properties with 
specificity to N-acetylneuraminic acid and also reactivity 
with sialoglycoconjugates,  apparently exert ing 
regulatory functions in the immune system (Jiang et al., 
1988; Zeng et al., 1992). Its binding to the lymphokine, 
which is mediated by protein-protein recognition (Zeng 
et al., 1994a,b), can neutralize the factor-dependent 
inhibition of macrophage migration (Zeng et al., 1993). 
Histochemically, sarcolectin can be employed to localize 
MIF, as emphasized in a study that revealed a correlation 
of extent of binding in lung cancer with survival of 
patients (Kayser et al., 1994). On this experimental basis 
and due to the present lack of information on MIF 
expression in this area we correlated the presence of 
binding sites for sarcolectin with the development of 
RN. In the present study we demonstrate characteristic 
binding patterns that differ from the distribution of fibrin 
and fibronectin, respectively. Thus, it is tempting to 
speculate on a participation of MIF in RN-related 
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Fig. 1. Schematic representation of the structure of the RN to define the 
nomenclature used in this investigation. 
processes and on the potential for interference of such 
effects by sarcolectin. However, owing to the complexity 
of the inflammatory process, care should be exerted in 
interpreting morphological data. 
Material and methods 
Rheumatoid nodules 
Subcutaneous nodules were removed from 23 
patients (16 females17 males) under local anaesthesia. 
Each had erosive disease that satisfied ARA criteria for 
classical RA (MacGregor, 1994). All patients had a 
positive latex agglutination assay result for rheumatoid 
factor. The median age was 59 years (27-78 years), and 
the mean disease duration was 9 years (3-24 years). The 
nodules were grouped according to the duration of the 
manifestation. Lesions that had been present between 4- 
9 months were classified as early RN. Their maximum 
diameter ranged between 8 and 19 mm. The remaining 
18 specimens had been present for more than 21 months. 
They were referred to as mature RN. Their diameters 
varied between 1 2  and 36 mm. All biopsies were 
immediately fixed in 10% neutral-buffered form01 
saline, dehydrated and embedded in paraffin according 
to standard methods. Five normal dermal biopsies, 
treated identically, served as controls. 
Biochemical procedures 
Sarcolectin was purified from human placenta by a 
standard procedure involving pepsin digestion, gel 
filtration on Sephacryl S-200 columns and fractionation 
on DEAE cellulose (Jiang et al., 1984; Zeng et al., 
1994a,b). Biotinylation without impairment of its MIF- 
binding capacity was achieved with biotinamidocaproyl 
hydrazide and ethyldimethylaminopropyl carbodiimide 
dissolved in dimethylsulfoxide and pyridine-HC1 (pH 
4.8) and polyclonal ant ibodies  against human 
recombinant MIF were produced in goats according to 
standard procedures (Gabius et al., 1991; Kayser et al., 
1993). 
Histochemical examination of tissue sections 
Serial 6 p m  sections were mounted on gelatine- 
coated glass-slides (Menzel, Braunschweig, FRG), 
deparaffinised and rehydrated. Endogenous peroxidase- 
activity was blocked with 0.3% H202 in methanol for 30 
min. To minimize non-specific binding reactions, 
specimens were successively covered for 15 min with 
0.1% bovine serum albumin, with a solution of avidin, 
then with a solution of biotin in phosphate buffer (PBS), 
followed by rinsing three times in PBS. Specimens were 
incubated with either biotinylated sarcolectin (45 min) or 
primary antibodies (Table 1) at room temperature. When 
necessary, sections were treated for 20 min with 0.1% 
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Table 1. Commercially available monoclonal and polyclonal* primary antibodies applied in the present study. 
ANTIBODY SPECIES SOURCE DIGESTION REFERENCE CELUANTIGEN SPEClFlClTY 
OKM-I mouse Ortho Talle et al., 1983 monocytedrnacrophages 
PG-M1 mouse Dako + Falini et al., 1993 macrophageslCD 68 
AMH 152 mouse Dianova + Stastny and Nunez, 1984 activated macrophages 
FMC 4 mouse Biozol + Zola and Kupa, 1990 HLA-DR, non complement fixing 
A 245* rabbit Dako + Christensen, 1990 fibronectin 
AHP 061* sheep Carnon Kudryk et al., 1984 fibrinogen 
trypsin (pH 7.8; 0.1% CaC12) (Kirkpatrick and 
D'Ardenne, 1984). In the case of primary antibodies, 
sections were reacted for an additional 30 min with 
biotinylated species-specific secondary antibodies 
(Dianova, Hamburg, FRG). Demonstration of the 
binding reaction was carried out according to Hsu et al. 
with the avidin-biotin-peroxidase (ABC) technique 
(ABC-Vectastain, Wiesbaden, FRG) (Hsu et al., 1981). 
The kit reagent-binding sites were visualised by 
incubation with a fresh solution of 0.02% H202 and 
0.1% diaminobenzidine hydrochloride for 5 min. F~nally, 
the samples were dehydrated, cleared and mounted. The 
intensity of binding reactions was graded subjectively 
and scored as negative: -, faintly visible: (t), weak: t ,  
medium: t t ,  and strong: t + + .  Control experiments 
consisted in the omission of labelled sarcolectin, the 
primary antibodies or avidin, respectively. 
Results 
Early rheumatoid nodules 
Very often the necrotic centre  was not fully 
surrounded by palisading cells, making it sometimes 
difficult to delineate the classical structure of the RN. In 
one specimen multiple independent foci of necrosis were 
detected in serial sections. In three small (and presum- 
ably recent) biopsies a nearly uniform distribution of 
patchy sarcolectin-binding structures could be demon- 
strated (Fig. 2). Especially phagocytes and endothelial 
cells displayed a high binding affinity (Fig. 3), and 
cytoplasm of epitheloid cells reacted moderately. The 
staining intensity gradually decreased towards the 
surrounding unaltered connective tissue, showing no 
definite border. Immunoperoxidase reactions for MIF 
and fibrin revealed an analogous distribution, except that 
endothelial cells were not labelled by anti-MIF, whereas 
fibrin-positivity was restricted to few vessels that 
additionally showed distinct inflammatory alterations. 
Fibronectin staining was especially pronounced in 
necrotic areas. Most of the palisading cells revealed the 
macrophage markers OKM 1 or PG-M1, respectively, 
whereas the percentage of cells binding FMC 4 or AMH 
152 was slightly reduced. Cell debris in the outer zone of 
necrotic areas also stained positive, whereas the central 
region was completely negative. Plasma cells and T 
lymphocytes were most prominent in the vascular zone. 
Only few (c  1%) scattered polymorph leukocytes were 
observed. 
In the remaining two RNs the extracellular structures 
of the central core revealed no affinity for sarcolectin. 
Fibronectin or fibrin expression, respectively, was 
demonstrated in only slight amounts. Few dispersed 
macrophages were intensely positive for all three 
markers. In contrast to appearances in the central region, 
the extracellular matrix at the periphery of the necrotic 
zone ("fibrillary area") was intensely labelled by 
sarcolectin. Additionally, vascular cells together with 
surrounding connective tissue were intensely stained. 
The remaining fibres in the intermediate as well as in the 
peripheral zones showed a significantly reduced affinity 
or  were (nearly) negative. Epitheloid-like cells 
constantly revealed no binding reaction. After incubation 
with MIF-specific antibodies significant parts of the 
necrotic core were labelled to a moderate amount. In the 
intermediate or peripheral zones results were nearly 
identical compared with sarcolectin, except that 
vasculature was constantly negative. Fibrin deposition 
was mainly restricted to perivascular tissue or (rarely) to 
vessel walls and intravascular thrombi. Fibronectin was 
seen between the palisading phagocytes in slight 
amounts, as  well as in moderate quantity in the 
connective tissue of the inner peripheral zone (Fig. 4). 
Its extent of expression was significantly less in the 
vascular zone, gradually declining towards the periphery. 
Mature rheumatoid nodules 
In all specimens from biopsies the characteristic 
complex structure with its radial arrangement could be 
detected. Histochemical analysis revealed that most cells 
of the palisade layer reacted positively with the mono- 
cytelmacrophage-specific antibodies OKM I, FMC 4, 
PG-M1 or AMH 152, respectively. In serial sections it 
could be documented that multiple necrotic centres with 
localised small extensions were the rule. The extra- 
cellular matrix of necrotic cores showed no or only faint 
binding reactivity for sarcolectin. Dispersed histiocyte- 
like cells were invariably positive, although binding 
affinity varied significantly between different patients. In 
contrast, fibrillary debris in the outer part of necrotic 
zones was constantly labelled with high intensity. In the 
intermediate and peripheral zones morphological 
findings could be clearly divided into two groups. In two 
specimens sarcolectin-binding sites were diffusely 
dispersed within the extracellular matrix, resembling the 
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results seen in "early RNs" (Fig. 5) .  Likewise, the 
binding intensity decreased towards the surrounding 
mature connective tissue. The cytoplasm of aggregated 
macrophages stained moderately positive as well. In the 
remaining 16 specimens palisaded cells revealed no 
affinity and extracellular fibres were not or only weakly 
positive. As a consequence an annular corona was 
formed around the necrotic centre of RNs. Additionally, 
endothelial cells as well as perivascular fibres were 
constantly stained with high intensity (Fig. 6). No 
significant difference was observed between the 
distribution patterns of sarcolectin-binding molecules 
and the staining results after incubation with MIF- 
antibody (Fig. 7), except that endothelial cells and 
perivascular structures were negative. In all sections 
investigated, fibronectin and fibrin were CO-distributed 
in the necrotic zone. Whereas the central core showed 
only slight affinity, binding intensity increased towards 
the palisaded macrophages infiltrating the clefts between 
the innermost palisaded cells. Significant presence of 
fibronectin was additionally detected in the connective 
tissue outwardly of the palisaded layer, whereas fibrin 
presence was restricted to occasional perivascular areas 
andlor intravascular thrombi. 
Control specimens 
Only in two specimens a faint labelling of 
endothelial cells by biotinylated sarcolectin was 
observed, the remaining structures being constantly 
negative. No binding reaction was detected after 
incubation with antibodies specific for MIF, fibrin or 
fibronectin, respectively. Only few dispersed histiocytes 
reacted for OKM I and PG-M1, whereas FMC 4 and 
AMH 152 were constantly negative. 
Discussion 
The objective of the present study was to histo- 
chemically demonstrate that sarcolectin-binding proteins 
like the lymphokine macrophage migration inhibitory 
factor are expressed in the granulomatous tissue of RNs. 
However, several difficulties are inherent in an approach 
to integrate our results into the pathogenic framework 
associated with the necrotising process. The objections 
partly reside in the slow proceeding over periods of 
monthslyears during evolution of RN lesions. 
Additionally, subtle but distinct differences between 
different areas of the same biopsy exist in the expression 
of morphological markers used as  inflammatory 
parameters (i.e. number of inflammatory cells or 
deposition of fibrin). Especially the choice of mono- 
clonal antibodies applied to delineate cellular activity 
can significantly influence judgement (Bernhagen et al., 
1998). Analogous conclusions have been drawn 
explaining rheumatoid joint pathology (Lindblad and 
Hedfors, 1985). Therefore, the morphological findings 
have to be interpreted very carefully. However, our 
immunhistochemical studies concerning cellular 
components of the inflammatory reaction correspond 
with results published in the literature (Palmer et al., 
1987; Melbye et al., 1991; Edwards et al., 1993). Most 
of the palisading cells revealed macrophage markers. 
Additionally, presence of the glycoproteins fibrin and 
fibronectin correlates with the distribution patterns 
reported in previous studies (Holund and Clemmensen, 
1984). Therefore, it seems reasonable to assume that the 
RNs analysed in this investigation are characteristic 
granulomata in RA. 
Until recently it was thought that activated T-cells 
were the primary, if not exclusive, sites of MIF synthesis 
(Calandra et al., 1994). According to this opinion non- 
specific deposition during the course of sustained 
inflammation has to be discussed, because T-cells are 
only a minor component of the inflammatory infiltrate in 
RNs (Firestein, 1998). However, it is now known that 
activated epithelia1 as well as mesenchymal cells in 
many tissues and also macrophages synthesize MIF 
(Wistow et al., 1993; Paralkar and Wistow, 1994). It was 
speculated that this protein may have a general 
involvement in the process of proliferation and 
differentiation. Significant parallels in the spatial pattern 
of expression with reference to N-myc were mentioned 
by the same authors, although not further specified 
(Wistow et al., 1993). Interestingly, high expression of 
oncogenes seems to be mainly restricted to aggregated 
synovial cells in seropositive RA (Asahara et al., 1997). 
Recent research has documented that sarcolectin 
seems to be at least related to a physiological subfraction 
of serum albumin, its impact on regulation of immune 
processes currently being unclear (Kayser et al., 1994; 
Zeng et al., 1994a,b). It is reasonable that not only 
inflammation-inducing cytokines, but also inhibitory 
factors seem to be involved in the formation of the RN. 
With respect to the binding patterns of the MIF-specific 
antibodies and of sarcolectin, close similarities with few 
differences were constantly detected. This was especially 
true for vascular structures that were intensely labelled 
by sarcolectin. It is presently not possible to decide 
unequivocally whether another sarcolectin-binding 
protein is present in these compartments or whether MIF 
presentation to the immuno- and ligand-histochemical 
tools yielded the differences. It can be relevant to note 
that human albumin or  subfractions thereof can 
specifically bind to endothelial receptors (Ghinea et al., 
1989). Besides protein-protein recognition, lectin- 
carbohydrate interactions also have to be considered, 
because it was shown that certain negatively charged 
glycoconjugates can inhibit binding reactions between 
sarcolectin and MIF in a concentration-dependent 
manner (Zeng and Gabius, 1992). A plethora of different 
mechanisms modifies carbohydrate composition of 
connective tissue during sustained inflammation. The 
patterns of glycoproteins can be significantly altered by 
inflammation-induced secretion of matrix molecules 
through local cells andlor by exsudation of serum 
factors. Additionally, i t  has been shown that substrate 
glycosylation can be dramatically modified by cytokines 
Sarcolectin-specific receptors in rheumatoid nodules 
(van Dijk et al., 1994). Of crucial importance, however, 
seems to be the release of multiple enzymes partially 
degrading proteoglycan sequences as well as the 
oligosaccharide part of glycoproteins. As a result 
significantly altered glycoconjugate structures are 
induced that often exhibit atypical carbohydrates in 
terminal position, leading to notably modified lectin- 
binding patterns. Recent studies have shown that 
misdirected glycosylation is of crucial importance in 
numerous stages of the inflammatory process in 
connective tissue (Hounsell and Davies, 1993). 
However, their impact in this context is presently 
speculative, but not proven. Combined histochemical 
and cell biological investigations are now required to 
clarify the importance of MIF-sarcolectin interactions in 
RN. 
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